Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial Biogen Idec, 21 Oct 2011 Accessed on 4 Jan 2012 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1619878. CommentRecommendBookmarkWatch